CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

No causal effects of plasma homocysteine levels on the risk of coronary heart disease or acute myocardial infarction: A Mendelian randomization study Percutaneous Support Devices for Percutaneous Coronary Intervention Switching P2Y12-receptor inhibitors in patients with coronary artery disease Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non–ST-Segment Elevation Myocardial Infarction An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Healed Culprit Plaques in Patients With Acute Coronary Syndromes

Original ResearchVolume 13, Issue 10, May 2020

JOURNAL:JACC: Cardiovascular Interventions Article Link

Evaluation and Management of Nonculprit Lesions in STEMI

T Thim, NW van der Hoeven, C Musto et al. Keywords: CFR; FFR; iFR; nonculprit coronary lesions; STEMI

ABSTRACT

Nonculprit lesions are frequently observed in patients with ST-segment elevation myocardial infarction. Results from recent randomized clinical trials suggest that complete revascularization after ST-segment elevation myocardial infarction improves outcomes. In this state-of-the-art paper, the authors review these trials and consider how best to determine which nonculprit lesions require revascularization and when this should be performed.